Year: 2023

Issy-les-Moulineaux, France – December 11th, 2023 An action-oriented barometer: identifying and activating the change levers towards more sustainable diets. Sodexo reveals the results of the first international sustainable food barometer carried out in partnership with the research and opinion polls institute Harris Interactive. Conducted in 2023 among more than 5,000 people in Brazil, France, the United Kingdom and the United States, this exclusive study breaks down the disparities between people’s representations of sustainable food and their associated behaviors for the first time. This action-oriented barometer aims to identify the concrete obstacles as well as the levers to induce changes in eating habits and accelerate the shift towards more sustainable diets. Sophie Bellon, Chairwoman of Sodexo’s Board of Directors...

SHELL PLC THIRD QUARTER 2023 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS December 11, 2023 The Board of Shell plc today announced the pounds sterling and euro equivalent dividend payments in respect of the third quarter 2023 interim dividend, which was announced on November 2, 2023 at US$0.331 per ordinary share. Shareholders have been able to elect to receive their dividends in US dollars, euros or pounds sterling. Holders of ordinary shares who have validly submitted US dollars, euros or pounds sterling currency elections by December 1, 2023 will be entitled to a dividend of US$0.331, €0.3070 or 26.31p per ordinary share, respectively. Absent any valid election to the contrary, persons holding their ordinary shares through Euroclear Nederland will receive their dividends in euros at the euro rate per ordinary share shown above. Absent...

HALF-YEAR 2023/2024 RESULTS PARIS, FRANCE (December 11, 2023 – 8.00 am CET) – Atari® — one of the world’s most iconic consumer brands and interactive entertainment producers — today announced the Group’s consolidated results for the half year ended September 30, 2023, approved by the Board of Directors during its meeting held on December 8, 2023. The half-year financial statements were the subject of a limited review by its Statutory Auditors. The half-year financial report is available on Atari’s investors relation website https://atari-investisseurs.fr/en/. Highlights for the first-half ended September 30, 2023Acquisition of GTI catalog of retro games Update to listing on OTC markets in the United States Acquisition of M Network Atari 2600 titles and related trademarks Acquisition of Nightdive Studios, Inc. (“Nightdive”) €30M...

Press Release Nokia and BT Group sign agreement to drive new 5G monetization opportunities through telco APIs  Memorandum of understanding covers the utilization of Nokia’s Network as Code platform and developer portal with BT Group’s cloud-native network11 December 2023 Espoo, Finland – Nokia and BT Group today announced an agreement to develop new 5G network monetization opportunities through Nokia’s Network as Code platform with developer portal (platform) and BT Group’s cloud-native network. BT Group, which operates EE – the UK’s best mobile network1 – is, like other communications service providers, looking to Nokia’s growing ecosystem of developer partners to gain access to simplified network capabilities in the form of software code that can be built into applications for enterprise, industrial, and consumer use cases. The...

Coop Pank’s financial results in November 2023:In November, number of the bank’s clients increased by 2,600 and number of active clients increased by 1,400. By the end of the month number of clients reached 180,300 and number of active clients reached 80,800. Over the year, customer base has grown by 25%. Volume of the bank’s customer deposits increased by 18 million euros, reaching 1.78 billion euros by the end of month. Deposits of corporate customers increased by 3 million euros and deposits of private customers increased by 5 million euros. The volume of deposits attracted from international platforms increased by 10 million euros. Over the year, volume of bank deposits has grown by 22%. The bank’s loan portfolio remained at the same level in November as it was in October and reached 1.50 billion euros by the end...

Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas1,2 New data reinforce the potential of combination regimens in earlier treatment settings and add to the robust body of evidence supporting ongoing Phase III studies3,4,5,6Basel, 11 December 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its CD20xCD3 T-cell engaging bispecific antibody programme, including eight oral presentations, were presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, 9-12 December 2023. Based on 32-month and 3-year follow-ups of two pivotal studies for fixed-duration treatments of Columvi® (glofitamab) and Lunsumio® (mosunetuzumab), respectively, data show that remissions were maintained...

Ad hoc announcement pursuant to Art. 53 LRPhase III APPEAR-C3G study met its primary endpoint, demonstrating superiority of iptacopan vs. placebo in proteinuria reduction at six-month analysis1; the safety profile of iptacopan was consistent with previously reported data1-3C3 glomerulopathy (C3G) is an ultra-rare complement-mediated kidney disease, with approximately 50% of patients progressing to kidney failure within 10 years of diagnosis4-7; currently no treatments address the underlying cause of C3G7-9Novartis plans to review results with global health authorities to enable potential submissions in 2024; data will be submitted for presentation at an upcoming medical meetingIptacopan demonstrated positive Phase III results in IgA nephropathy (IgAN) at the interim analysis and a late-stage development program is ongoing across...

Allschwil, Switzerland, December 11, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that its license partner Astellas Pharma US, Inc. (“Astellas”) received the approval of Cresemba® (isavuconazole) for the treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients by the US Food and Drug Administration (FDA). Cresemba for injection is approved for adults and now for pediatric patients 1 year of age and older. Cresemba capsules are approved for adults and now for pediatric patients 6 years of age and older, who weigh 16 kilograms and greater. Dr. Marc Engelhardt, Chief Medical Officer of Basilea, said: “We congratulate Astellas on the approval of Cresemba...